Tenofo-B Drug Interactions

Didanosine: Co-administration of tenofovir disoproxil fumarate and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse events. Didanosine should be discontinued in patients who develop didanosine-associated adverse events.
Atazanavir: Tenofovir disoproxil fumarate affects the pharmacokinetics of atazanavir. Tenofovir disoproxil fumarate should only be administered with boosted atazanavir (ATZ 300 mg/RTV 100 mg).
Triple therapy with nucleoside/nucleotides: High rates of virological failure and of emergence of resistance at early stage in HIV patients occurred when tenofovir disoproxil fumarate was combined with lamivudine and abacavir as well as lamivudine and didanosine as a once daily regimen. Patients on a therapy utilizing a triple nucleoside-only regimen should be carefully monitored and considered for treatment modification.
Tacrolimus/Other medicinal products affecting renal function: Since tacrolimus can affect renal function, close monitoring is recommended when it is co-administered with tenofovir disoproxil fumarate. Co-administration of tenofovir disoproxil fumarate with other medicinal products that decrease or compete for renal clearance may increase serum concentrations of tenofovir disoproxil fumarate.
HIV and HBV co-infection: Due to the risk of development of HIV resistance, tenofovir disoproxil fumarate should only be used as part of an appropriate antiretroviral combination regimen in HIV/HBV co-infected patients.